Direct-acting antiviral agents in the treatment of chronic Hepatitis C – “Real-life” experience from an academic centre and two specialized clinical practices

Abstract

The introduction of the new direct antiviral agents has revolutionized the therapy of chronic hepatitis C. Today we are able to cure the vast majority of our patients with an 8- to 12-week therapy course of an antiviral combination therapy with an excellent safety profile. Real-life data are very important to further develop our experience with the new therapeutics and help us to improve the care of our patients in our everyday clinical practice.

In our study, we present the retrospective analysis of a representative German cohort of 344 patients with chronic hepatitis C treated with the new direct antiviral agents. The patients were recruited in an academic center of southern Germany (University Clinic of Ulm, Clinic of Internal Medicine I) and in 2 highly specialized clinical practices in the city center and the near region of Ulm. Within this in-detail characterized study cohort, we analyzed the efficacy and safety of antiviral therapy under real-life conditions.

In 322 patients, we could document SVR12 data and found an excellent overall SVR12 rate of 97.8 % across all genotypes. In more detail, we could show comparable SVR12 results of 99 % and 99.2 % in patients with the hepatitis C virus subtypes 1a and 1b of and an excellent SVR12 rate of 93.1 % in genotype 3 patients without liver cirrhosis. Nevertheless, SVR12 rates tend to be lower in patients with the presence of liver cirrhosis, especially in genotype 3 patients with the lowest SVR12 rate in the whole study group of only 80 %. In general, there were no major safety issues except of 1 patient treated with a protease-inhibitor-based regimen who developed a generalized skin reaction and needed hospitalization and premature end of antiviral therapy.

In summary, our analysis of this well characterized representative cohort of 344 patients adds more information in the field of real-life experience with the new antiviral therapeutics and could therefore contribute to improve the care of our patients. Together with the existing real-life data, we now can proceed in achieving the aim of viral eradication of hepatitis C virus within our population.

Zusammenfassung

Die Einführung der neuen direkt antiviral wirksamen Medikamente hat die Therapie der chronischer Hepatitis C revolutioniert. Heute sind wir in der Lange die überwiegende Mehrheit unserer Patienten mit einer 8 – 12 Wochen dauernden und überaus sicheren antiviralen Kombinationstherapie zu heilen. „Real-Life“ Daten sind überaus wichtig um unsere Erfahrungen mit den neuen Therapeutika zu verbessern und uns bei der Versorgung unserer Patienten im klinischen Alltag zu unterstützen.

In der vorliegenden Studie haben wir eine repräsentative Kohorte mit 344 Patienten mit chronischer Hepatitis C, die mit den neuen direkt antiviral wirksamen Substanzen behandelt wurden retrospektiv analysiert. Die Erhebung der Patientendaten erfolgte in der Hepatitis C-Sprechstunde der Klinik für Innere Medizin I am Universitätsklinikum Ulm und in zwei Schwerpunktpraxen (eine infektiologische und eine gastroenterologische Praxis) in Ulm und der nahen Umgebung Ulms. Wir führten eine detaillierte Analyse dieser Patientenkohorte bezüglich der Wirksamkeit und Sicherheit der neuen direkt antiviral wirksamen Medikamente durch.

Bei 322 Patienten konnten wir die HCV-RNA 12 Wochen nach Therapieende dokumentieren und fanden eine exzellente SVR12 Rate von insgesamt 97,8 % über alle Genotypen hinweg. Die SVR12 Rate betrug beim Genotyp 1a 99 %, beim Genotyp 1b 99,2 % und 93,1 % bei Patienten mit Genotyp 3 ohne Leberzirrhose. Dennoch war die SVR12 Rate tendenziell niedriger bei Patienten, insbesondere bei Genotyp 3 Patienten, die mit 80 % die niedrigste SVR12 Rate im gesamten Kollektiv aufwiesen. Im Allgemeinen gab es keine relevanten Sicherheitsbedenken, lediglich bei einer Patientin, die eine Proteasenhibitor-haltige Therapie erhielt kam es zu einer ausgeprägten generalisierten Hautreaktion mit nachfolgendem stationären Aufenthalt und vorzeitigem Abbruch der antiviralen Therapie.

Zusammenfassend erweitert unsere Analyse dieser sehr gut charakterisierten Patientenkohorte mit insgesamt 344 Patienten den Kenntnisstand bezüglich der Anwendung der neuen antiviralen Therapien im klinischen Alltag und trägt hierdurch zur Verbesserung der Versorgung dieser Patienten bei. Gemeinsam mit den bereits vorliegenden „real-life“ Daten, kommen wir dadurch dem übergeordneten Ziel der Elimination der Hepatitis C-Infektion in unserer Bevölkerung näher.

Schlüsselwörter

Hepatitis C - direkt-antiviral wirksame Medikamente - SVR12 - „Real-life“ Daten

Key words

hepatitis C - direct-acting antiviral agents - SVR12 - real-life data

• References

• 1 Webster DP, Klenermann P, Dusheiko GM. Hepatitis C. Lancet 2015; 385: 1124-1135
• 2 Blachier M, Leleu H, Peck-Radosavljevic M. et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608
• 3 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562
• 4 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576
• 5 Ramos-Casals M, Zignego AL, Ferri C. et al. International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV). Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol 2017; 66: 1282-1299
• 6 Fried MW, Shiffman ML, Reddy KR. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
• 7 Jakobsen JC, Nielsen EE, Feinberg J. et al. Direct-acting antiviral agents for chronic hepatitis C. Cochrane Database Syst Rev 2017; 6
• 8 Zeuzem S. Treatment options in hepatitis C – the current state of the art. Dtsch Arztebl Int 2017; 114: 11-21
• 9 Kowdley KV, Gordon SC, Reddy KR. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
• 10 Zeuzem S, Ghalib R, Reddy KR. et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1-13
• 11 Feld JJ, Jacobson IM, Hézode C. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-25607
• 12 Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories. J Viral Hepat 2017; 24: 442-453
• 13 Toshikuni N. Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver 2017; 11: 335-348
• 14 McCarty TR, Lim JK. Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opin Pharmacother 2017; 18: 165-174
• 15 Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M. Hepatitis C: efficacy and safety in real life. Liver Int 2017; 37 (Suppl. 01) 26-32
• 16 Arends JE, Kracht PA, Hoepelman AI. et al. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016; 22: 846-852
• 17 Galgenmueller S, Jaeger H, Kratzer W. et al. Parameters affecting different acoustic radiation force impulse applications in the diagnosis of fibrotic liver changes. World J Gastroenterol 2015; 21: 8425-8432
• 18 Andreone P, Colombo MG, Enejosa JV. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365
• 19 Ferenci P, Bernstein D, Lalezari J. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992
• 20 Knowdley KV, Gordon SC, Reddy KR. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
• 21 Poordad F, Hezode C, Trinh R. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982
• 22 Zeuzem S, Jacobson IM, Baykal T. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614
• 23 Afdhal N, Reddy KR, Nelson DR. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
• 24 Afdhal N, Zeuzem S, Kwo P. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898
• 25 Feld JJ, Kowdley KV, Coakley E. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603
• 26 Naggie S, Cooper C, Saag M. et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705-713
• 27 Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12: 1371-1380
• 28 Backus LI, Boothroyd DB, Phillips BR. et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47
• 29 Ioannou GN, Beste LA, Chang MF. et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 2016; 151: 457-471
• 30 Sulkowski MS, Vargas HE, Di Bisceglie AM. et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150: 419-429
• 31 Younossi ZM, Park H, Gordon SC. et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care 2016; 22: SP205-SP211
• 32 Werner CR, Schwarz JM, Egetemeyr DP. et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22: 8050-8059
• 33 Stahmeyer JT, Rossol S, Bert F. et al. Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment. Z Gastroenterol 2016; 54: 760-769
• 34 European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236
• 35 Sarrazin C, Berg T, Buggisch P. et al. S3 guideline hepatitis C addendum. Z Gastroenterol 2015; 53: 320-334
• 36 Lai JB, Witt MA, Pauly MP. et al. Eight- or 12-week treatment of hepatitis C with ledipasvir/sofosbuvir: real-world experience in a large integrated health system. Drugs 2017; 77: 313-318
• 37 Kowdley KV, Sundaram V, Jeon CY. et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65: 1094-1103
• 38 Foster GR, Irving WL, Cheung MC. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224-1231
• 39 Cornberg M, Petersen J, Schober A. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017; 45: 688-700
• 40 Foster GR, Afdhal N, Roberts SK. et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-2617
• 41 Sarrazin C, Dvory-Sobol H, Svarovskaia ES. et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 2016; 151: 501-512
• 42 Bourlière M, Gordon SC, Flamm SL. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376: 2134-2146